- call +1-201-465-4211
- email sales@mrinsights.biz
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
Scope of the Report:
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
The global Secondary Hyperparathyroidism Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Secondary Hyperparathyroidism Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Secondary Hyperparathyroidism Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Secondary Hyperparathyroidism Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Shire
Sanofi
Deltanoid Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Secondary Hyperparathyroidism Treatment Market Overview
1.1 Product Overview and Scope of Secondary Hyperparathyroidism Treatment
1.2 Classification of Secondary Hyperparathyroidism Treatment by Types
1.2.1 Global Secondary Hyperparathyroidism Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Types in 2017
1.2.3 Surgery
1.2.4 Drugs
1.2.5 Vitamin D
1.2.6 Calcimimetics
1.2.7 Phosphate Binders
1.3 Global Secondary Hyperparathyroidism Treatment Market by Application
1.3.1 Global Secondary Hyperparathyroidism Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Global Secondary Hyperparathyroidism Treatment Market by Regions
1.4.1 Global Secondary Hyperparathyroidism Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Secondary Hyperparathyroidism Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Secondary Hyperparathyroidism Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Secondary Hyperparathyroidism Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Secondary Hyperparathyroidism Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Secondary Hyperparathyroidism Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Secondary Hyperparathyroidism Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 OPKO Health
2.2.1 Business Overview
2.2.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 AbbVie
2.3.1 Business Overview
2.3.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AbbVie Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Astellas Pharma
2.4.1 Business Overview
2.4.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Roche
2.5.1 Business Overview
2.5.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Roche Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 KAI Pharmaceuticals
2.6.1 Business Overview
2.6.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 Kyowa Hakko Kirin
2.7.1 Business Overview
2.7.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 Leo Pharma
2.8.1 Business Overview
2.8.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 Shire
2.9.1 Business Overview
2.9.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Shire Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.10 Sanofi
2.10.1 Business Overview
2.10.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Sanofi Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.11 Deltanoid Pharmaceuticals
2.11.1 Business Overview
2.11.2 Secondary Hyperparathyroidism Treatment Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Secondary Hyperparathyroidism Treatment Market Competition, by Players
3.1 Global Secondary Hyperparathyroidism Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Secondary Hyperparathyroidism Treatment Players Market Share
3.2.2 Top 10 Secondary Hyperparathyroidism Treatment Players Market Share
3.3 Market Competition Trend
4 Global Secondary Hyperparathyroidism Treatment Market Size by Regions
4.1 Global Secondary Hyperparathyroidism Treatment Revenue and Market Share by Regions
4.2 North America Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
5 North America Secondary Hyperparathyroidism Treatment Revenue by Countries
5.1 North America Secondary Hyperparathyroidism Treatment Revenue by Countries (2013-2018)
5.2 USA Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
6 Europe Secondary Hyperparathyroidism Treatment Revenue by Countries
6.1 Europe Secondary Hyperparathyroidism Treatment Revenue by Countries (2013-2018)
6.2 Germany Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
6.4 France Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Secondary Hyperparathyroidism Treatment Revenue by Countries
7.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Revenue by Countries (2013-2018)
7.2 China Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
7.5 India Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
8 South America Secondary Hyperparathyroidism Treatment Revenue by Countries
8.1 South America Secondary Hyperparathyroidism Treatment Revenue by Countries (2013-2018)
8.2 Brazil Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Secondary Hyperparathyroidism Treatment by Countries
9.1 Middle East and Africa Secondary Hyperparathyroidism Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Secondary Hyperparathyroidism Treatment Revenue and Growth Rate (2013-2018)
10 Global Secondary Hyperparathyroidism Treatment Market Segment by Type
10.1 Global Secondary Hyperparathyroidism Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Secondary Hyperparathyroidism Treatment Market Forecast by Type (2018-2023)
10.3 Surgery Revenue Growth Rate (2013-2023)
10.4 Drugs Revenue Growth Rate (2013-2023)
10.5 Vitamin D Revenue Growth Rate (2013-2023)
10.6 Calcimimetics Revenue Growth Rate (2013-2023)
10.7 Phosphate Binders Revenue Growth Rate (2013-2023)
11 Global Secondary Hyperparathyroidism Treatment Market Segment by Application
11.1 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Application (2013-2018)
11.2 Secondary Hyperparathyroidism Treatment Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacies Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
12 Global Secondary Hyperparathyroidism Treatment Market Size Forecast (2018-2023)
12.1 Global Secondary Hyperparathyroidism Treatment Market Size Forecast (2018-2023)
12.2 Global Secondary Hyperparathyroidism Treatment Market Forecast by Regions (2018-2023)
12.3 North America Secondary Hyperparathyroidism Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Secondary Hyperparathyroidism Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Secondary Hyperparathyroidism Treatment Revenue Market Forecast (2018-2023)
12.6 South America Secondary Hyperparathyroidism Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Secondary Hyperparathyroidism Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Secondary Hyperparathyroidism Treatment Picture
Table Product Specifications of Secondary Hyperparathyroidism Treatment
Table Global Secondary Hyperparathyroidism Tr
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
